FindTrial
Sign In

Osteoporosis in PBC

Study for the relationship between primary biliary cholangitis and osteoporosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000029152
Enrollment
Unknown
Registered
2020-01-16
Start date
2020-01-20
Completion date
Unknown
Last updated
2020-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis

Interventions

Four cohorts:none

Sponsors

Second Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Diagnostic criteria for PBC patients: (1) Biochemical indexes reflecting cholestasis such as ALP increase; (2) Serum AMA or ama-2 positive; (3) Histopathology of liver in accordance with PBC; Two of the three criteria can be diagnosed. 2. Diagnostic criteria for PSC patients: (1) Intermittent / persistent jaundice; (2) ALP and GGT increased with abnormal liver function; (3) ERCP diagnosis suggests "bead like" or "dead tree like" changes in intrahepatic and extrahepatic bile ducts; (4) Pathological examination of "onion skin" like fibrosis; (5) No cholelithiasis, no history of biliary operation, no congenital abnormality of catheter; (6) Excluding cholangiocarcinoma, PBC and no evidence of secondary sclerosing cholangitis; 3. Diagnosis standard of PBC + AIH patients: on the basis of meeting the diagnosis of PBC: (1) ALT >=5 UNL; (2) Serum IgG should be at least more than 2unl or SMA positive; (3) Liver tissue examination showed moderate or severe peripheral or lobular septal lymphoclastic necrosis; 4. Non - aid diagnostic criteria: the rest of the non - aid patients.

Exclusion criteria

Exclusion criteria: (1) Patients and their families do not agree to participate in sample extraction and provide necessary medical history; (2) Patients with severe hypertension, coronary heart disease, cardiopulmonary insufficiency and malignant tumor; (3) Patients with decompensated liver function (child III / IV); (4) Long term use of glucocorticoids; (5) Pregnant women and those who are not convenient for BMD examination.

Design outcomes

Primary

MeasureTime frame
BMD;bone resorption;bone formation;ALT;AST;ALP;GGT;bilirubin;Pathological stage of liver;—

Secondary

MeasureTime frame
Age;sex;weight;—

Countries

China

Contacts

Public ContactJin-hui Yang

Second Affiliated Hospital of Kunming Medical University

17787003686@163.com+86 13608712810

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026